These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 35887085

  • 1. Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
    Noriega-Rivera R, Rivera-Serrano M, Rabelo-Fernandez RJ, Pérez-Santiago J, Valiyeva F, Vivas-Mejía PE.
    Int J Mol Sci; 2022 Jul 13; 23(14):. PubMed ID: 35887085
    [Abstract] [Full Text] [Related]

  • 2. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
    Bonito NA, Borley J, Wilhelm-Benartzi CS, Ghaem-Maghami S, Brown R.
    Clin Cancer Res; 2016 Jun 15; 22(12):3097-3104. PubMed ID: 26763252
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
    Wang Y, Wang H, Song T, Zou Y, Jiang J, Fang L, Li P.
    Mol Med Rep; 2015 Aug 15; 12(2):2211-6. PubMed ID: 25824616
    [Abstract] [Full Text] [Related]

  • 7. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
    Teng PN, Bateman NW, Wang G, Litzi T, Blanton BE, Hood BL, Conrads KA, Ao W, Oliver KE, Darcy KM, McGuire WP, Paz K, Sidransky D, Hamilton CA, Maxwell GL, Conrads TP.
    Hum Cell; 2017 Jul 15; 30(3):226-236. PubMed ID: 28251557
    [Abstract] [Full Text] [Related]

  • 8. HOXB2 promotes cisplatin resistance by upregulating lncRNA DANCR in ovarian cancer.
    Li X, Zheng Z, Zhou W, Huang H, Zhou Y, Xu Q, Zhu X, Teng Y.
    J Ovarian Res; 2024 Jun 08; 17(1):124. PubMed ID: 38851728
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS-mediated mechanisms.
    Zhang X, Liao X, Wang M, Liu J, Han J, An D, Zheng T, Wang X, Cheng H, Liu P.
    Cancer Sci; 2024 Apr 08; 115(4):1170-1183. PubMed ID: 38287874
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.
    Dai C, Xu P, Liu S, Xu S, Xu J, Fu Z, Cao J, Lv M, Zhou J, Liu G, Zhang H, Jia X.
    Arch Gynecol Obstet; 2021 May 08; 303(5):1271-1281. PubMed ID: 33151424
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
    Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen ST.
    Carcinogenesis; 2014 May 08; 35(5):1100-9. PubMed ID: 24379240
    [Abstract] [Full Text] [Related]

  • 15. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C, Wang M, Shi C, Shi F, Pei C.
    Biosci Trends; 2018 Jul 17; 12(3):309-316. PubMed ID: 29952351
    [Abstract] [Full Text] [Related]

  • 16. ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.
    Böpple K, Oren Y, Henry WS, Dong M, Weller S, Thiel J, Kleih M, Gaißler A, Zipperer D, Kopp HG, Aylon Y, Oren M, Essmann F, Liang C, Aulitzky WE.
    Cell Death Dis; 2024 Apr 24; 15(4):290. PubMed ID: 38658567
    [Abstract] [Full Text] [Related]

  • 17. Long non-coding RNA HOXA11-AS knockout inhibits proliferation and overcomes drug resistance in ovarian cancer.
    Chen Y, Cui Z, Wu Q, Wang H, Xia H, Sun Y.
    Bioengineered; 2022 May 24; 13(5):13893-13905. PubMed ID: 35706412
    [Abstract] [Full Text] [Related]

  • 18. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H, Fang L, Jiang J, Kuang Y, Wang B, Shang X, Han P, Li Y, Liu M, Zhang Z, Li P.
    Cell Death Dis; 2018 Oct 30; 9(11):1103. PubMed ID: 30375398
    [Abstract] [Full Text] [Related]

  • 19. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB, Joseph P, Kovalenko O, Singh S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S, DiFeo A.
    Oncotarget; 2015 Sep 15; 6(27):23720-34. PubMed ID: 26125441
    [Abstract] [Full Text] [Related]

  • 20. Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin.
    Xu Q, Liu Y, Wang S, Wang J, Liu L, Xu Y, Qin Y.
    BMC Cancer; 2022 Jun 08; 22(1):628. PubMed ID: 35672728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.